Company intelligence / Profile preview
XNK Therapeutics
Huddinge, Swedenxnktherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
XNK Therapeutics AB develops unique and individualized NK cell-based immunotherapies for cancer. Its lead asset, Evencaleucel, has reached Phase 2 trials for multiple myeloma. Other pipeline assets target various hematological and solid tumors at earlier stages of development. The company leverages a proprietary platform to generate autologous or allogeneic NK cells with enhanced anti-tumor activity.
- Therapeutic areas
- Oncology
- Modalities
- Natural Killer (NK) cell therapiesCAR-NK cell therapiesCell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships publicly disclosed as of May 2025.
Beyond the preview
Go deeper on XNK Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XNK Therapeutics.